What Baseline Disease Severity Hides in PsA Trial Data, With David Oberlin, MDByDavid Oberlin, MDSeptember 9th 2026David Oberlin, MD, on why trial enrichment, not mechanistic superiority, likely explains differing radiographic results in PsA drug trials.